Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?
09:34am, Friday, 08'th Oct 2021
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m
WATERTOWN, Mass.--(BUSINESS WIRE)--New Preclinical Data for EDP-235, Enanta's Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference
Enanta To Discontinue Internal Development Of NASH Candidates
04:29pm, Monday, 04'th Oct 2021
After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now
Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021
07:00am, Friday, 01'st Oct 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
07:00am, Monday, 23'rd Aug 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript
12:37pm, Sunday, 08'th Aug 2021
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates
07:46pm, Thursday, 05'th Aug 2021
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 15.60% and -1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
05:30pm, Wednesday, 14'th Jul 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral HBV RNA Destabilizer, at the International Liver Congress (EASL)
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript
01:39am, Monday, 10'th May 2021
Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript
Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA
09:58am, Friday, 07'th May 2021
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
06:47pm, Thursday, 06'th May 2021
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -15.96% and -21.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stoc
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
01:49pm, Wednesday, 28'th Apr 2021
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Bottom Fishing Club: Enanta Pharmaceuticals
05:13am, Monday, 08'th Mar 2021
Enanta's huge cash holdings are very desirable in an uncertain economic world and overvalued U.S. stock market setup. The drug trial pipeline could have several positive news developments in the comin
